Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer.

ABSTRACT:

Background

Systemic corticosteroids (SCs) are associated with reduced survival in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) monotherapy. However, the current first-line standard of care usually involves combined chemotherapy (CT) and ICIs, and the effect of SCs on survival under combined CT and ICI has never been studied.

Objectives

To investigate the association between SC therapy and survival under CT-ICI in advanced-stage NSCLC patients.

Design

We performed a multicenter retrospective cohort study of all advanced-stage NSCLC patients receiving first-line CT-ICI.

Methods

The primary endpoint was progression-free survival (PFS) according to SC exposure status (⩾10 mg/day), adjusted in a multivariate C

SUBMITTER: Roboubi A 

PROVIDER: S-EPMC11811968 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature